PRKCD as a potential therapeutic target for chronic obstructive pulmonary disease

Siqi Li; Qiong Huang; Dongbo Zhou; Baimei He

doi:10.1016/j.intimp.2022.109374

PRKCD as a potential therapeutic target for chronic obstructive pulmonary disease

Int Immunopharmacol. 2022 Dec;113(Pt A):109374. doi: 10.1016/j.intimp.2022.109374. Epub 2022 Oct 21.

Authors

Siqi Li¹, Qiong Huang², Dongbo Zhou³, Baimei He⁴

Affiliations

¹ Department of Geriatric Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, China; Department of Geriatric Medicine, Xiangya Hospital, Central South University, Changsha 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China. Electronic address: lsq199706@163.com.
² Department of Geriatric Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, China; Department of Geriatric Medicine, Xiangya Hospital, Central South University, Changsha 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China. Electronic address: huangqiong1998@163.com.
³ Department of Geriatric Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, China; Department of Geriatric Medicine, Xiangya Hospital, Central South University, Changsha 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China. Electronic address: zhoudb532311@163.com.
⁴ Department of Geriatric Respiratory and Critical Care Medicine, Xiangya Hospital, Central South University, Changsha 410008, China; Department of Geriatric Medicine, Xiangya Hospital, Central South University, Changsha 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha 410008, China. Electronic address: hebaimei@126.com.

PMID: 36279664
DOI: 10.1016/j.intimp.2022.109374

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a common respiratory disease characterized by progressive airflow limitation and abnormal lung function due to noxious particles and gases. Although many measures are available, COPD remains one of the leading causes of morbidity and mortality worldwide. Therefore, there is an urgent need to discover novel potential therapeutic targets for COPD. Protein kinase C delta (PRKCD) is a member of thePKCfamily and possesses various biological properties. Recently, PRKCD has been reported to play an important role in the pathogenesis of COPD. However, the mechanisms of PRKCD on COPD are not fully elucidated.

Aim: In this review, we will discuss the roles and mechanisms of PRKCD involved in the development of COPD.

Methods: We systematically summarized the studies on the research progress of PRKCD in COPD based on MEDLINE/PubMed databases.

Conclusions: PRKCD contributes to the development of COPD by promoting inflammatory response, apoptosis, mitochondrial dysfunction and MUC5AC hypersecretion. These data provide evidence that PRKCD might be a potential therapeutic target for COPD.

Keywords: Apoptosis; Chronic obstructive pulmonary disease; Inflammation; MUC5AC; Mitochondrial function; Protein kinase C delta.

Publication types

Review

MeSH terms

Apoptosis
Humans
Lung / pathology
Protein Kinase C-delta*
Pulmonary Disease, Chronic Obstructive* / pathology

Substances

Protein Kinase C-delta
PRKCD protein, human